» Articles » PMID: 36833334

Molecular Evolution of SARS-CoV-2 During the COVID-19 Pandemic

Overview
Journal Genes (Basel)
Publisher MDPI
Date 2023 Feb 25
PMID 36833334
Authors
Affiliations
Soon will be listed here.
Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produced diverse molecular variants during its recent expansion in humans that caused different transmissibility and severity of the associated disease as well as resistance to monoclonal antibodies and polyclonal sera, among other treatments. In order to understand the causes and consequences of the observed SARS-CoV-2 molecular diversity, a variety of recent studies investigated the molecular evolution of this virus during its expansion in humans. In general, this virus evolves with a moderate rate of evolution, in the order of 10-10 substitutions per site and per year, which presents continuous fluctuations over time. Despite its origin being frequently associated with recombination events between related coronaviruses, little evidence of recombination was detected, and it was mostly located in the spike coding region. Molecular adaptation is heterogeneous among SARS-CoV-2 genes. Although most of the genes evolved under purifying selection, several genes showed genetic signatures of diversifying selection, including a number of positively selected sites that affect proteins relevant for the virus replication. Here, we review current knowledge about the molecular evolution of SARS-CoV-2 in humans, including the emergence and establishment of variants of concern. We also clarify relationships between the nomenclatures of SARS-CoV-2 lineages. We conclude that the molecular evolution of this virus should be monitored over time for predicting relevant phenotypic consequences and designing future efficient treatments.

Citing Articles

SARS-CoV-2 introductions to the island of Ireland: a phylogenetic and geospatiotemporal study of infection dynamics.

Rice A, Troendle E, Bridgett S, Firoozi Nejad B, McKinley J, Bradley D Genome Med. 2024; 16(1):150.

PMID: 39702217 PMC: 11658175. DOI: 10.1186/s13073-024-01409-1.


Lack of memory recall in human CD4 T cells elicited by the first encounter with SARS-CoV-2.

Richards K, Changrob S, Thomas P, Wilson P, Sant A iScience. 2024; 27(6):109992.

PMID: 38868209 PMC: 11166706. DOI: 10.1016/j.isci.2024.109992.


Molecular characterization of SARS-CoV-2 Omicron clade and clinical presentation in children.

Scutari R, Fox V, Fini V, Granaglia A, Vittucci A, Smarrazzo A Sci Rep. 2024; 14(1):5325.

PMID: 38438451 PMC: 10912656. DOI: 10.1038/s41598-024-55599-0.


Unraveling the genetic evolution of SARS-CoV-2 Recombinants using mutational dynamics across the different lineages.

Ravi V, Shamim U, Khan M, Swaminathan A, Mishra P, Singh R Front Med (Lausanne). 2024; 10:1294699.

PMID: 38288302 PMC: 10823376. DOI: 10.3389/fmed.2023.1294699.


Transmission of SARS-CoV-2 in free-ranging white-tailed deer in the United States.

Feng A, Bevins S, Chandler J, DeLiberto T, Ghai R, Lantz K Nat Commun. 2023; 14(1):4078.

PMID: 37429851 PMC: 10333304. DOI: 10.1038/s41467-023-39782-x.


References
1.
Huang Y, Yang C, Xu X, Xu W, Liu S . Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020; 41(9):1141-1149. PMC: 7396720. DOI: 10.1038/s41401-020-0485-4. View

2.
Karbalaei M, Keikha M . Deltacron is a recombinant variant of SARS-CoV-2 but not a laboratory mistake. Ann Med Surg (Lond). 2022; 79:104032. PMC: 9212869. DOI: 10.1016/j.amsu.2022.104032. View

3.
Szemiel A, Merits A, Orton R, MacLean O, Pinto R, Wickenhagen A . In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. PLoS Pathog. 2021; 17(9):e1009929. PMC: 8496873. DOI: 10.1371/journal.ppat.1009929. View

4.
Tay J, Porter A, Wirth W, Duchene S . The Emergence of SARS-CoV-2 Variants of Concern Is Driven by Acceleration of the Substitution Rate. Mol Biol Evol. 2022; 39(2). PMC: 8807201. DOI: 10.1093/molbev/msac013. View

5.
Chan-Yeung M, Xu R . SARS: epidemiology. Respirology. 2004; 8 Suppl:S9-14. PMC: 7169193. DOI: 10.1046/j.1440-1843.2003.00518.x. View